12th May 2016 BSBMT Scientific Day

Presentations now available with permissions. More to follow..


- Targeting immune regulation at the tumour site - Dr Sergio Quezada, UCL Cancer Institute, London

- Immune checkpoint blockade in solid tumours - Dr James Larkin, Royal Marsden Hospital, London

- Immune checkpoint blockade with ipilimumab in patients with haematologic malignancies who relapse after allogeneic haematopoietic cell transplantation - Dr Matthew Davids , Dana Faber Cancer Institute, Boston

- The evolving role of stem cell transplant and checkpoint inhibition and other novel therapies in NHL - Dr Patrick Jonhston, Mayo Clinic, Minnesota

Session 2: BSBMT Open Meeting

President’s Report - Dr Charles Crawley
CTC Report - Charles Crawley on behalf of Andy Peniket
Treasurer’s Report - Dr Fiona Dignan
Data Registry Report - Mrs Keiren Kirkland

Session 3:The John Goldman Abstract Prize

- Identification of mutatations prognostic of relapse after allogeneic transplantation and novel clone emergence at disease recurrence: implications for strategies to prevent post transplant relapse - Dr Paul Ferguson, Queen Elizabeth Hospital

- Targeting the TCR-beta-constant region for diagnosis and treatment of T-cell malignancies- Dr Paul Maciocia, University College London

- Phase I/II trial in high-risk paediatric patients post allogeneic haematopoietic stem cell transplant (HSCT) treated with ex vivo expanded donor derived adenovirus-specific T cells - Dr Dr Juliana Silva, GOSH

- An operational definition of primary refractory acute myeloid leukaemia which allows early identification of patients who may benefit from allogeneic stem cell transplantation - Dr Paul Ferguson, Queen Elizabeth Hospital Abstract Prize Winner!

- Haploidentical BMT with a post-infusion of stem cells cyclophosphamide approach is feasible and leads to a high rate of donor engraftment in haemoglobinopathies allowing universal application of transplantation- Dr Viaml Kumar, St Mary’s Hospital

- Impact of conditioning regimen on outcomes for children with acute myeloid leukaemia transplanted in first complete remission- Dr Giovanna Lucchini, GOSH

Session 4

- Defining measurable residual disease in AML and using it for therapeutic decisions - challenges and prospects- Dr Sylvie Freemen, University of Birmingham